A Single and Multiple-Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Efinopegdutide (MK-6024) in Otherwise Healthy Obese Participants and the Effect of Multiple Doses of Efinopegdutide on the Pharmacokinetics of Acetaminophen
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Efinopegdutide (Primary) ; Paracetamol
- Indications Liver cirrhosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 26 Feb 2025 Status changed from active, no longer recruiting to completed.
- 27 Nov 2024 New trial record